National Patent Development Corp Bar-Ilan University Israel joint venture corporation Scientific Testing Inc begin clinical trial U.S. immuno-augmenting compound AS101 treatment Acquired Immune Deficiency Syndrome (AIDS). The study conduct Institute Immunological Disorders (MD Anderson Hospital Houston Tex) direction Dr Peter Mensell pursuant investigational drug application file Food Drug Administration company said. The study expect begin six week design test effect AS101 30 AIDS patient National Patent said. It add AS101 proprietary synthetic compound invent Bar-Ilan University doctor show immuno-augmenting anti-viral anti-tumor activity preclinical animal test immuno-augmenting activity limited AIDS patient phase foreign clinical tests. Reuter 